Search clinical trials for: MK-8245

Total 1783 results

Okayama University
Merck Sharp & Dohme LLC

Recruiting

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast Carcinoma

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Metastatic Hormone-Sensitive Prostate Cancer

China
Genexine, Inc.
Merck Sharp & Dohme LLC

Completed

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Triple Negative Breast Cancer

Korea, Republic of
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Alliance Foundation Trials, LLC.
Merck Sharp & Dohme LLC

Completed

Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

Non-Small Cell Lung Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer

Metastatic Colorectal Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study of Islatravir (MK-8591) in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)

HIV-1
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

Childhood Acute Lymphoblastic Leukemia | Adult Acute Lymphoblastic Leukemia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)

Osteoporosis
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Renal Cell Carcinoma
University of California, Davis
Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Recurrent Bladder Carcinoma | Stage III Urethral Cancer | Stage IV Urethral Cancer | Urethral Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma | Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter | Stage III Bladder Urothelial Carcinoma | Recurrent Urothelial Carcinoma of... and other conditions

United States
Organon and Co

Withdrawn

A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142) (RESPOND-EUROPE)

Osteoarthritis
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013) (RESTORE-IMI 1)

Bacterial Infections
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

Osteoporosis Postmenopausal
Merck Sharp & Dohme LLC

Completed

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Breast Cancer | Breast Neoplasms
M.D. Anderson Cancer Center
Bristol-Myers Squibb; Merck Sharp & Dohme LLC; Commonwealth Foundation for Cancer...

Terminated

Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

Breast Cancer

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Metastatic Esophageal Squamous Cell Carcinoma

Argentina, Chile, United States, Canada, China, Costa Rica, Denmark, France, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Romania, Ukraine, Singapore, Ma... and more
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
The Christie NHS Foundation Trust
Merck Sharp & Dohme LLC; University of Manchester; Liverpool Clinical Trials...

Recruiting

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma (CAPER)

Metastatic Renal Cell Carcinoma

United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Non-small Cell Lung Cancer

China, Taiwan, Japan, Korea, Republic of, United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Italy, Mexico, Spain, Sweden, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)

Non-small Cell Lung Cancer
University of Michigan Rogel Cancer Center
Medical College of Wisconsin

Completed

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)

Schizophrenia
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Organon and Co

Completed

An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)

Hypercholesterolemia
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

United States
University Hospitals Cleveland Medical Center

Active, not recruiting

Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers

Post-acute COVID-19 Syndrome

United States
Merck Sharp & Dohme LLC

Completed

Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) (7625ACNPhase3)

Complicated Intra-abdominal Infections

China
Merck Sharp & Dohme LLC

Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma

United States
Roswell Park Cancer Institute
United States Department of Defense

Recruiting

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Metastatic Malignant Neoplasm in the Brain

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Clear Cell Renal Cell Carcinoma

United States
Organon and Co

Terminated

A Phase 2 Trial to Evaluate if Corifollitropin Alfa (Org 36286), Followed by a Low Daily Dose of hCG or Recombinant FSH Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility (P05693)

Ovulation Induction
ArQule, Inc. (a wholly owned subsidiary of Merck...

Terminated

Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)

Cancer | Solid Tumors

United States
Organon and Co

Withdrawn

An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)

Infertility
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)

Primary Insomnia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

Fungal Infection
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)

Primary Insomnia
ANRS, Emerging Infectious Diseases

Completed

Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir

Hepatitis C
Glenmark Pharmaceuticals Ltd. India

Completed

To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).

Osteoarthritis

United States
Filipa Lynce, MD
Merck Sharp & Dohme LLC; Zentalis Pharmaceuticals

Recruiting

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Breast Cancer | Triple Negative Breast Cancer | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor Negative Malignant Tumor Breast Triple

United States
Providence Health & Services

Available

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

KRAS G12V Mutant Advanced Epithelial Cancers
Merck Sharp & Dohme LLC

Terminated

A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)

Postmenopausal Osteoporosis
National Cancer Institute (NCI)

Completed

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditions

United States, Canada
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Colorectal Carcinoma | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer

United States
Merck Sharp & Dohme LLC

Terminated

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

Multiple Myeloma
Hopital St. Georges, Ajaltoun
Omicron Pharmaceuticals; Nattopharma ASA

Unknown

Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7) (DECAV-K2)

Aortic Valve Disease

Lebanon

Search clinical trials for: MK-8245

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations